X0306 4/A 2022-07-19 2022-07-25 0 0001827506 Talaris Therapeutics, Inc. TALS 0001365343 Nader Francois C/O TALARIS THERAPEUTICS, INC. 93 WORCESTER STREET WELLESLEY MA 02481 1 0 0 0 Common Stock 2022-07-19 4 P 0 50000 3.52 A 50000 D Common Stock 2022-07-20 4 P 0 52000 3.62 A 102000 D Common Stock 2022-07-21 5 J 0 E 248432 0.00 D 147255 I By Francois Nader 2020 Trust Common Stock 2022-07-21 5 J 0 E 248432 0.00 A 248432 I By FN TALS LLC Common Stock 2022-07-21 4 P 0 36500 3.72 A 138500 D Common Stock 2022-07-25 5 J 0 E 138500 0.00 D 0 D Common Stock 2022-07-25 5 J 0 E 138500 0.00 A 386932 I By FN TALS LLC The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.38 to $3.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.51 to $3.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration. These shares are held in a trust for the benefit of the Reporting Person's spouse and child. The Reporting Person''s spouse and child are trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.595 to $3.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration. This amendment is being filed solely to correct the number of shares reported by the Francois Nader 2020 Trust, which was incorrectly reported due to an administrative error. /s/ Mary Kay Fenton, attorney-in-fact 2022-09-13